先看重點
在1946年英國出生佇列中465名無失智者裡,53歲時收縮壓每高10 mm Hg,69-71歲MRI上的腦白質高訊號體積(WMHV)平均大7%(95%置信區間1-14)。血壓與β澱粉樣蛋白狀態和認知評分無關,且這是隻涉及一個出生年份的觀察性佇列。
證據類型
世代研究
解讀依據
公開摘要
閱讀重點
關聯與混雜
研究在問什麼
中年高血壓會增加日後認知障礙的風險,但風險暴露的敏感時期,以及損害是透過澱粉樣蛋白還是血管機制介導,目前瞭解不多。作者想弄清成年期的血壓或其變化是否、以及在何時與晚年的腦結構、病理和認知相關。
研究對象與方法
分析來自Insight 46,這是醫學研究理事會全國健康與發育調查的神經科學子研究,該出生佇列最初有5362人,均於1946年同一週在英國出生。69-71歲的參與者均無失智,接受容積MRI、氟貝他吡PET澱粉樣蛋白成像和認知測試(臨床前阿爾茨海預設知綜合評分,PACC)。血壓分別在36、43、53、60-64和69歲測量,並計算各年齡之間的變化。結局包括WMHV、β澱粉樣蛋白陽性、全腦和海馬體積以及PACC,使用廣義線性、logistic和線性迴歸並校正潛在混雜因素。2015年5月28日至2018年1月10日共評估502人,465人納入影像分析(男性238人[51%];平均年齡70.7歲;β澱粉樣蛋白陽性83人[18%])。
主要發現
以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。
- 153歲時血壓較高、43至53歲之間血壓升幅較大,與69-71歲MRI上更多的腦白質損傷相關:收縮壓每高10 mm Hg,平均WMHV高7%(95%置信區間1-14,p = 0.024);舒張壓每高10 mm Hg,高15%(95%置信區間4-27,p = 0.0057)。
- 2每變化1個標準差,收縮壓對應的WMHV高15%(95%置信區間3-29,p = 0.012),舒張壓對應的WMHV高15%(95%置信區間3-30,p = 0.017)。
- 343歲時舒張壓較高與69-71歲全腦體積較小相關(每高10 mm Hg為-6.9 mL,95%置信區間-11.9至-1.9,p = 0.0068),36至43歲之間舒張壓升幅較大也是如此(每1個標準差-6.5 mL,95%置信區間-11.1至-1.9,p = 0.0054)。
- 436至43歲之間收縮壓升幅較大,與海馬體積較小相關(每1個標準差-0.03 mL,95%置信區間-0.06至-0.001,p = 0.043)。
- 5絕對血壓及其變化均不能預測β澱粉樣蛋白狀態或PACC評分。
限制與不確定性
- 1僅分析了465人,均來自同一年齡的英國出生佇列且無失智,結果未必適用於其他族群或世代。
- 2研究在多個年齡和多個結局之間做了許多比較,部分效應接近臨界(如p = 0.043),海馬體積的差異非常小。
- 3作者未發現血壓在該年齡影響認知或澱粉樣蛋白的證據,因此這裡並未證明血壓與失智風險本身相關。
- 4作為觀察性研究,它不能證明在40歲左右降壓就能保護大腦;本解讀僅基於摘要。
日常健康啟示
這項研究支援從中年甚至更早就把血壓控制好,因為血壓偏高且持續上升與幾十年後更多的小血管損傷和較小的腦體積相關。但它並未證明40歲開始治療就能預防這些變化。血壓目標和治療決定應由醫師做出。
如何連結自己的資料
家用上臂血壓計是最直接相關的裝置。請在每天同一時間、坐姿放鬆後、使用同一臺血壓計測量,看多次讀數的平均值以及數月乃至數年的變化,而不要只看一次讀數;並把記錄帶給醫師。
如何理解這類證據
暴露先於追蹤期間的結果,仍可能存在混淆和反向因果。風險比不是個人絕對風險,也不等於已證明的介入效果。
作者的結構化摘要 English
以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。
Background
Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition.
Methods
Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born throughout mainland Britain in one week in 1946. Participants aged 69-71 years received T1 and FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University College London (London, UK); all participants were dementia-free. Blood pressure measurements had been collected at ages 36, 43, 53, 60-64, and 69 years. We also calculated blood pressure change variables between ages. Primary outcome measures were white matter hyperintensity volume (WMHV) quantified from multimodal MRI using an automated method, amyloid-β positivity or negativity using a standardised uptake value ratio approach, whole-brain and hippocampal volumes quantified from 3D-T1 MRI, and a composite cognitive score-the Preclinical Alzheimer Cognitive Composite (PACC). We investigated associations between blood pressure and blood pressure changes at and between 36, 43, 53, 60-64, and 69 years of age with WMHV using generalised linear models with a gamma distribution and log link function, amyloid-β status using logistic regression, whole-brain volume and hippocampal volumes using linear regression, and PACC score using linear regression, with adjustment for potential confounders.
Findings
Between May 28, 2015, and Jan 10, 2018, 502 individuals were assessed as part of Insight 46. 465 participants (238 [51%] men; mean age 70·7 years [SD 0·7]; 83 [18%] amyloid-β-positive) were included in imaging analyses. Higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at age 53 years and greater increases in SBP and DBP between 43 and 53 years were positively associated with WMHV at 69-71 years of age (increase in mean WMHV per 10 mm Hg greater SBP 7%, 95% CI 1-14, p=0·024; increase in mean WMHV per 10 mm Hg greater DBP 15%, 4-27, p=0·0057; increase in mean WMHV per one SD change in SBP 15%, 3-29, p=0·012; increase in mean WMHV per 1 SD change in DBP 15%, 3-30, p=0·017). Higher DBP at 43 years of age was associated with smaller whole-brain volume at 69-71 years of age (-6·9 mL per 10 mm Hg greater DBP, -11·9 to -1·9, p=0·0068), as were greater increases in DBP between 36 and 43 years of age (-6·5 mL per 1 SD change, -11·1 to -1·9, p=0·0054). Greater increases in SBP between 36 and 43 years of age were associated with smaller hippocampal volumes at 69-71 years of age (-0·03 mL per 1 SD change, -0·06 to -0·001, p=0·043). Neither absolute blood pressure nor change in blood pressure predicted amyloid-β status or PACC score at 69-71 years of age.
Interpretation
High and increasing blood pressure from early adulthood into midlife seems to be associated with increased WMHV and smaller brain volumes at 69-71 years of age. We found no evidence that blood pressure affected cognition or cerebral amyloid-β load at this age. Blood pressure monitoring and interventions might need to start around 40 years of age to maximise late-life brain health.
Funding
Alzheimer's Research UK, Medical Research Council, Dementias Platform UK, Wellcome Trust, Brain Research UK, Wolfson Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.
來源與署名
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
Lane CA, Barnes J, Nicholas JM, Sudre CH, Cash DM, Parker TD, Malone IB, Lu K, James SN, Keshavan A, Murray-Smith H, Wong A, Buchanan SM, Keuss SE, Gordon E, Coath W, Barnes A, Dickson J, Modat M, Thomas D, Crutch SJ, Hardy R, Richards M, Fox NC, Schott JM.
The Lancet. Neurology · 2019-08-20
DOI: 10.1016/s1474-4422(19)30228-5 ↗PubMed · 31444142 ↗Europe PMC · 所記錄的開放授權: cc by ↗摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。
MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱
來源查核日期 2026-11-01
實用健康指南
放在一起讀
晝夜活動節律紊亂與更高的死亡風險相關(109,365人)
在7項觀察性研究、共109,365名參與者中,晝夜活動對比較弱(相對振幅較低)與更高的心血管死亡風險(風險比[HR]1.50,95%置信區間1.13至1.98)和全因死亡風險(HR 1.46,95%置信區間1.27至1.68)相關。證據基礎小,又是觀察性的,不能說明改善節律就能降低風險,疾病本身也可能擾亂節律。
Journal of the American Heart Association
五類運動都降低了靜息血壓,等長訓練降幅最大
彙總270項隨機試驗、共15,827名參與者的結果,有氧、抗阻、聯合、間歇和等長訓練與無介入對照組相比都降低了靜息血壓(各P<0.001),其中等長訓練降幅最大:收縮壓下降8.24 mm Hg,舒張壓下降4.00 mm Hg。各方式之間的排序部分來自間接比較,各試驗也不盡相同,所以排序不是個人的運動處方。
British Journal of Sports Medicine
鹽替代品使中國農村高危族群的中風、主要心血管事件和死亡率下降
在中國農村600個村莊、20,995名有中風史或年齡在60歲及以上且有高血壓的人中,使用鹽替代品(氯化鈉75%、氯化鉀25%)的中風發生率低於普通鹽:平均追蹤4.74年,每1000人年29.14次對33.65次(率比0.86,95%置信區間0.77至0.96;P=0.006)。死亡也更低(率比0.88),嚴重高鉀血癥事件沒有顯著增多,但試驗為開放標籤設計,且在中國農村開展。
The New England Journal of Medicine
智慧手錶脈搏不規則提醒較少見,做貼片檢查者34%確有房顫
在419,297名沒有已知心房顫動(房顫)的蘋果手錶使用者中,0.52%收到脈搏不規則提醒;返還可用心電貼片的450人中,34%確認有房顫(97.5%置信區間29至39)。提醒發出時恰有貼片記錄的,通知的陽性預測值為0.84(95%置信區間0.76至0.92),但收到提醒者中僅20.8%返還了貼片,沒有收到提醒的人未被監測,所以手錶沒有提醒並不能排除房顫。
The New England Journal of Medicine

